Cancer Patents (Class 514/19.3)
  • Patent number: 10782294
    Abstract: Isolated peptides and compositions comprising same are provided. Further, methods for targeting mitochondria in a cell, methods for assessing mitochondrial function in a cell and methods for diagnosing mitochondria associated diseases are provided.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 22, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Arnon Henn, Boris Shneyer, Andreas Reichert
  • Patent number: 10768179
    Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 8, 2020
    Assignees: National Cancer Center, Daiichi Sankyo Company, Limited
    Inventors: Takashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
  • Patent number: 10766942
    Abstract: The present invention provides an anti-angiogenic peptide comprising an amino acid sequence having at least 70% identity to amino acid residues 123-140 of SEQ ID NO 1 or amino acid residues 24-141 of SEQ ID NO 2. The invention also provides nucleic acid constructs encoding such peptides, and vectors and cells comprising such nucleic acid constructs. The invention further provides pharmaceutical compositions comprising the peptides or nucleic acid constructs of the invention, and the use of peptides, nucleic acid constructs or pharmaceutical compositions of the invention to treat diseases associated with angiogenesis.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 8, 2020
    Assignee: Queen Mary University of London
    Inventors: James Whiteford, Giulia De Rossi
  • Patent number: 10752893
    Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: August 25, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • Patent number: 10722593
    Abstract: Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed herein can be used to treat diseases such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 28, 2020
    Assignee: SIRENAS LLC
    Inventors: Oliver Booth Vining, Venkata Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Jacob Neal Beverage, Elizabeth Paige Stout, Bryan Junn Lee, Steven Bruce Cohen, Eduardo Esquenazi
  • Patent number: 10704082
    Abstract: Aspects of the technology disclosed herein relate to methods of preparing and analyzing nucleic acids. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 7, 2020
    Assignee: ArcherDX, Inc.
    Inventors: Joshua Stahl, Jason Myers, Brady Culver, Brian Kudlow
  • Patent number: 10696721
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • Patent number: 10689414
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 23, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Patent number: 10640569
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 5, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 10603309
    Abstract: A novel function for the p53 gene related to resolution of deep venous thrombosis is disclosed herein. Lack of the p53 gene results in impaired thrombus resolution in a clinically relevant in vivo model of deep venous thrombus resolution. It is further shown that augmentation of p53 activity with quinacrine accelerates thrombus resolution in vivo, and that this beneficial effect is completely dependent on p53. p53-based therapy is therefore provided to accelerate thrombus resolution in patients, and to prevent or ameliorate the debilitating long-term complications of deep venous thrombosis such as post-thrombotic syndrome.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 31, 2020
    Inventor: Rajabrata Sarkar
  • Patent number: 10568868
    Abstract: The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 25, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Jonathan Powell
  • Patent number: 10550179
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 4, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10548985
    Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 4, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Patent number: 10544201
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 28, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui
  • Patent number: 10538591
    Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: January 21, 2020
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Mariano S. Viapiano, Nandhu Mohan Sobhana, Ennio Antonio Chiocca
  • Patent number: 10519233
    Abstract: The present invention aims to provide: an immunostimulant useful for maintaining, enhancing or suppressing an immune function associated with CD300a activation signaling, or an immunomodulator as an immunosuppressant useful for suppressing the immune function; use of a CD300a gene-deficient mouse for pathology analysis and the like; an anti-CD300a antibody; and the like.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: December 31, 2019
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Akira Shibuya, Chigusa Oda, Satoko Tahara, Tsukasa Nabekura, Udayanga Sanath Kankanam Gamage, Haruka Miki, Syuichi Iino
  • Patent number: 10487126
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: November 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10435681
    Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Nadav Orr, Yair Pilpel, Sivan Doron
  • Patent number: 10426822
    Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 1, 2019
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Patent number: 10413586
    Abstract: An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: September 17, 2019
    Assignee: Melema Pharma GmbH
    Inventors: Hans Lentzen, Klaus Witthohn
  • Patent number: 10383931
    Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 20, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
  • Patent number: 10364270
    Abstract: Disclosed is related to a synthetic peptide consisting of an amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1). Also provided are a pharmaceutical composition benefic to eye care or eye health comprising the peptide, and a method for wound healing using the peptide.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 30, 2019
    Assignee: PRO SUNFUN BIOTECH RESEARCH AND DEVELOPMMENT CO., LTD.
    Inventors: Min-Chuan Huang, Syue-Ting Chen, Yu-Chun Liu
  • Patent number: 10357538
    Abstract: The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 23, 2019
    Assignee: NORTHERN SYDNEY LOCAL HEALTH DISTRICT
    Inventors: Ross Arthur Davey, Christopher John Weir
  • Patent number: 10350260
    Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: July 16, 2019
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: 10350262
    Abstract: The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. In some aspects the invention includes contacting a cancer cell with one or more exogenous methylation-controlled J protein (MCJ) agonist compounds to increase sensitivity of the cancer cell to one or more chemotherapeutic agents. In certain aspects the invention includes compounds and methods useful to kill cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 16, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Thomas Roberts, Tina Thornton
  • Patent number: 10344065
    Abstract: A method for treating Alzheimer's disease and a method for downregulating protein aggregation in brain are disclosed, which respectively comprises: administering a zinc finger-like peptide to a subject in need thereof, wherein the zinc finger-like peptide comprises an amino acid sequence of RRSSSCK (SEQ ID NO: 1).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 9, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Nan-Shan Chang, Yu-Min Kuo
  • Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10316077
    Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: June 11, 2019
    Assignee: Sapience Therapeutics, Inc.
    Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
  • Patent number: 10293024
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 21, 2019
    Assignee: Blueberry Therapeutics Limited
    Inventor: John Ridden
  • Patent number: 10292992
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 21, 2019
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10294276
    Abstract: The present invention describes a process for isolation of romidepsin from fermentation broth and preparation of crystals of romidepsin. The process of the invention includes fewer purification steps and provides romidepsin having purity of greater than 99.5% area by HPLC. The process of the invention involves simple purification steps and hence, does not require multiple chromatographic purification steps to achieve desired quality of romidepsin. The process is advantageous over reported processes in terms of 99.5% pure yield, fast process, less expensive and less cumbersome as multiple chromatographic purification is not necessary to achieve desired quality. The process for the preparation of crystals of romidepsin provides advantages like simple steps and involves use of single solvent. The process is advantageous in terms of time, cost, and simplicity.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: May 21, 2019
    Assignee: Concord Biotech Limited
    Inventors: Ankur S. Vaid, Anand M. Dhiman, Traunkant P. Sharma
  • Patent number: 10221417
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: March 5, 2019
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Jan Fiedler
  • Patent number: 10206975
    Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Swedish Orphan Biovitrum AB (PUBL)
    Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
  • Patent number: 10202456
    Abstract: Provided is a recombinant cell including inactivated pyruvate dehydrogenase kinase (PDK) gene, a composition for producing a polypeptide of interest including the recombinant cell, and a method of producing a polypeptide of interest using the recombinant cell.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 12, 2019
    Assignee: Samsung Bioepis Co., Ltd.
    Inventors: Eunyoung Park, Hye Young Suh, Hee Kyung Sung, Christina Yi, Sunkyu Kim
  • Patent number: 10196432
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: February 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventor: Jörn Dengiel
  • Patent number: 10189880
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: January 29, 2019
    Assignee: LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Mirjam H. M. Heemskerk, J. H. Frederik Falkenburg
  • Patent number: 10190174
    Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
  • Patent number: 10117946
    Abstract: The present invention relates to hydrogels comprising a first peptide with a covalently linked bioactive agent and optionally a second peptide. The present invention further relates to uses of the hydrogel for delivery of the bioactive agent or as an implant. The present invention further relates to drug delivery devices, implant, pharmaceutical or cosmetic compositions comprising the hydrogel. The present invention further relates to methods of local treatment of diseases and to methods for preparing the first peptide and the hydrogels.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: November 6, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Michael R. Reithofer, Charlotte A. E. Hauser, Kiat Hwa Chan, Archana Mishra
  • Patent number: 10087234
    Abstract: The invention relates to mimetic peptides of epitope(s) of Apolipoprotein A-I, diagnostic immunoassays comprising such mimetic peptides, as well as methods for diagnosing and methods for preventing and/or treating a cardiovascular disease.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 2, 2018
    Assignees: LES HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVE, HOFFMAN-LA ROCHE INC.
    Inventors: Nicolas Vuilleumier, Sabrina Pagano, Oliver Hartley, Hubert Gaertner, Priscila Camillo Teixeira, Paul Cutler, Philippe Ferber
  • Patent number: 10081810
    Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 25, 2018
    Assignees: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Qingguo Ruan, Youhai H. Chen, Tingting Fan, Yifan Ma, Lintao Cai, Shaowen Wang, Xiaochun Wan
  • Patent number: 10081654
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): (I) (VI) and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 25, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 10071154
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: September 11, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B Weiner, Matthew P Morrow
  • Patent number: 10072078
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: September 11, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
  • Patent number: 10064843
    Abstract: The present invention relates to a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a method of preparation thereof; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and health functional food for preventing or ameliorating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased because WJCPA-126 binds to CypA with high binding affinity exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: September 4, 2018
    Assignee: University-Industry Cooperation Group of Kyung Hee University
    Inventors: Sung Soo Kim, Won Jea Cho
  • Patent number: 10047138
    Abstract: Described herein are novel fusion proteins and nucleic acids encoding these fusion proteins. T cells into which such nucleic acids have been introduced are also contemplated. These T cells can express the fusion proteins on their cell surface. In various embodiments, these T cells can be used in assays to detect costimulatory ligands, inhibitors of costimulatory ligands, or inhibitors that can neutralize an inhibitor of a costimulatory ligand. Such assay methods are also described herein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AMGEN INC.
    Inventor: Christian Vettermann
  • Patent number: 10010541
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
  • Patent number: 9999655
    Abstract: Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Moerae Matrix, Inc.
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
  • Patent number: 9980956
    Abstract: Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 29, 2018
    Assignees: 3M INNOVATIVE PROPERTIES COMPANY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John Vasilakos, Willem Overwijk
  • Patent number: 9975885
    Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 22, 2018
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Sarah Emma St. John, Andrew D. Mesecar